City of Hope | Strategic Alliance Partners

April 01, 2024

Richard T. Lee, MD, discusses integrative oncology approaches and the development of the Cherng Family Center for Integrative Oncology at City of Hope.

March 29, 2024

Daneng Li, MD, discusses the implications of a study evaluating ADG126 in combination with pembrolizumab in patients with MSS colorectal cancer.

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

March 28, 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

March 28, 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

March 28, 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

March 27, 2024

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

March 25, 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

March 22, 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

March 21, 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

March 21, 2024

Side effect profiles driven by fruquintinib use are discussed.

March 18, 2024

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.

March 14, 2024

Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.

March 14, 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

March 14, 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

March 07, 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.